polygeline
Small moleculeexperimental
Haemaccel is a type of intravenous colloid used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to hemorrhage, loss of plasma, or loss of water and electrolytes from persistent vomiting and diarrhea. Haemaccel contains degraded gelatin. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02686151)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHaemaccel ↗
- ChEMBLCHEMBL2108135 ↗
Also known as
- gelatin solution, special intravenous
- polygeline
- polygeline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02686151 | Phase 3 | Apr 1, 2016 | Inner Mongolia Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inner Mongolia Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1